Oliver Lagore Vanvalin Investment Group Grows Stock Holdings in Agilent Technologies, Inc. (NYSE:A)

Oliver Lagore Vanvalin Investment Group lifted its holdings in Agilent Technologies, Inc. (NYSE:A) by 24.7% during the second quarter, Holdings Channel reports. The fund owned 11,625 shares of the medical research company’s stock after buying an additional 2,305 shares during the quarter. Oliver Lagore Vanvalin Investment Group’s holdings in Agilent Technologies were worth $1,507,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Crewe Advisors LLC boosted its position in Agilent Technologies by 114.8% in the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock worth $25,000 after purchasing an additional 101 shares in the last quarter. Livelsberger Financial Advisory purchased a new stake in Agilent Technologies during the fourth quarter worth $26,000. Ridgewood Investments LLC acquired a new stake in Agilent Technologies during the second quarter valued at $29,000. Rise Advisors LLC increased its holdings in Agilent Technologies by 527.8% in the first quarter. Rise Advisors LLC now owns 226 shares of the medical research company’s stock valued at $33,000 after buying an additional 190 shares in the last quarter. Finally, YHB Investment Advisors Inc. acquired a new position in shares of Agilent Technologies in the first quarter worth about $34,000. Hedge funds and other institutional investors own 87.42% of the company’s stock.

Insider Transactions at Agilent Technologies

In other news, SVP Dominique Grau sold 9,990 shares of the company’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $145.00, for a total value of $1,448,550.00. Following the transaction, the senior vice president now owns 40,011 shares of the company’s stock, valued at approximately $5,801,595. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,958 shares of the company’s stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total transaction of $283,910.00. Following the transaction, the chief executive officer now directly owns 24,118 shares in the company, valued at $3,497,110. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Dominique Grau sold 9,990 shares of Agilent Technologies stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total value of $1,448,550.00. Following the completion of the sale, the senior vice president now directly owns 40,011 shares of the company’s stock, valued at $5,801,595. The disclosure for this sale can be found here. Insiders sold 13,906 shares of company stock worth $2,006,580 in the last 90 days. Insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

A has been the subject of several recent analyst reports. Stifel Nicolaus restated a “buy” rating and issued a $151.00 price target on shares of Agilent Technologies in a research note on Monday, August 26th. UBS Group boosted their price objective on Agilent Technologies from $141.00 to $150.00 and gave the company a “neutral” rating in a research report on Thursday, August 22nd. Bank of America upped their target price on Agilent Technologies from $140.00 to $147.00 and gave the stock a “neutral” rating in a research note on Thursday, August 22nd. Wolfe Research lowered shares of Agilent Technologies from an “outperform” rating to a “peer perform” rating in a report on Thursday, June 27th. Finally, Barclays upped their price objective on shares of Agilent Technologies from $125.00 to $135.00 and gave the stock an “underweight” rating in a research report on Friday, August 23rd. One investment analyst has rated the stock with a sell rating, six have given a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $141.60.

Agilent Technologies Price Performance

NYSE:A opened at $148.06 on Friday. Agilent Technologies, Inc. has a one year low of $96.80 and a one year high of $155.35. The stock has a market cap of $43.20 billion, a PE ratio of 35.00, a P/E/G ratio of 6.48 and a beta of 1.05. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.37 and a current ratio of 1.78. The stock has a 50 day moving average price of $138.58 and a 200 day moving average price of $139.11.

Agilent Technologies (NYSE:A) last issued its earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.06. The business had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.56 billion. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. The company’s revenue for the quarter was down 5.6% on a year-over-year basis. During the same period last year, the company earned $1.43 EPS. Equities research analysts expect that Agilent Technologies, Inc. will post 5.24 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 23rd. Stockholders of record on Tuesday, October 1st will be paid a $0.236 dividend. The ex-dividend date is Tuesday, October 1st. This represents a $0.94 annualized dividend and a dividend yield of 0.64%. Agilent Technologies’s dividend payout ratio (DPR) is 22.22%.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.